https://scholars.lib.ntu.edu.tw/handle/123456789/641895
標題: | Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer | 作者: | Wang, Kang-Li Yeh, Tsung-Yu Hsu, Pei-Chen Wong, Tzu-Hsuan Liu, Jia-Rong JI-WANG CHERN Lin, Miao-Hsia CHAO-WU YU |
關鍵字: | ALK; HDAC; antimour; mutantresistance | 公開日期: | 十二月-2024 | 卷: | 39 | 期: | 1 | 起(迄)頁: | 2318645 | 來源出版物: | Journal of enzyme inhibition and medicinal chemistry | 摘要: | A series of novel benzimidazole derivatives were designed and synthesised based on the structures of reported oral available ALK inhibitor and HDAC inhibitor, pracinostat. In enzymatic assays, compound 3b, containing a 2-acyliminobenzimidazole moiety and hydroxamic acid side chain, could inhibit both ALK and HDAC6 (IC50 = 16 nM and 1.03 µM, respectively). Compound 3b also inhibited various ALK mutants known to be involved in crizotinib resistance, including mutant L1196M (IC50, 4.9 nM). Moreover, 3b inhibited the proliferation of several cancer cell lines, including ALK-addicted H2228 cells. To evaluate its potential for treating cancers in vivo, 3b was used in a human A549 xenograft model with BALB/c nude mice. At 20 mg/kg, 3b inhibited tumour growth by 85% yet had a negligible effect on mean body weight. These results suggest a attracting route for the further research and optimisation of dual ALK/HDAC inhibitors. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641895 | ISSN: | 14756366 | DOI: | 10.1080/14756366.2024.2318645 |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。